Trutect brings targeted therapy to canine parvovirus care

Elanco Animal Health’s canine parvovirus monoclonal antibody, now branded Trutect, received full USDA approval on December 15, 2025, making it the first and only fully approved targeted treatment for canine parvovirus in the U.S. The product was first conditionally licensed in March 2023, and its label expanded in June 2025 to include passive immunity for exposed puppies, giving veterinarians both a treatment and a prevention option in certain exposure settings. In Elanco’s first-year real-world data, 93% of puppies treated with the product survived, and treated patients spent an average of 1.87 fewer days hospitalized. (elanco.com)

Why it matters: For veterinary professionals, this is a meaningful shift in parvo care. Historically, clinics have relied on supportive care alone, but published JAVMA data found that early IV administration prevented mortality in all treated dogs in an experimental challenge model, versus 57% mortality in controls, while also reducing the severity or duration of diarrhea, vomiting, fever, lymphopenia, and fecal viral shedding. That could translate into better outcomes, shorter stays, lower operational strain, and another tool for shelters and high-volume practices managing outbreaks. Safety data submitted to USDA showed no anaphylactic reactions in a 147-dog field safety study, with injection site reactions reported in 4% of dogs. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for broader field adoption, post-approval experience in general practice and shelter medicine, and whether independent data confirm the product’s impact on hospitalization time, outbreak control, and cost of care. (elanco.com)